Title : Conserved antisense RNAs significantly inhibit pan-coronaviruses

Abstract:

The continuing pandemics of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and novel coronavirus disease 2019 (COVID-19) underscore the urgent need for the development of anti-pan-coronavirus drugs that can target emerging coronaviruses and their variants. Despite this pressing need, there is currently no experimental report effectively targeting pan-coronaviruses. In response to this challenge, we have invented a novel strategy employing conserved antisense RNAs against pan-coronaviruses (CAR-pCoV). The promising results of our study will be presented orally during the conference.

Biography:

Dr. Shen studied pharmacy at Nankai University, receiving his bachelor's degree in 2014. He then joined the research group of Professor Xinyi Lu at the State Key Laboratory of Medicinal Chemical Biology at Nankai University, receiving his doctorate in 2022. In 2023, he joined Shandong Jincheng Pharmaceutical Group Co., Ltd. as a senior R&D engineer. In 2024, he joined the faculty at Qilu Medical University, where he was promoted to associate professor. He has published 5 research papers in SCI(E) journals.